Compare · CNMD vs LIVN
CNMD vs LIVN
Side-by-side comparison of CONMED Corporation (CNMD) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.43B, about 3.4x CNMD ($1.30B).
- CNMD has been more active in the news (9 items in the past 4 weeks vs 1 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 16 for CNMD).
- Company
- CONMED Corporation
- LivaNova PLC
- Price
- -
- -
- Market cap
- $1.30B
- $4.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 9
- 1
- Recent ratings
- 16
- 20
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest CNMD
- SEC Form 4 filed by Executive Vice President & CFO Gallagher John E
- New insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)
- BMO Capital Markets initiated coverage on CONMED with a new price target
- SEC Form 4 filed by Director Martin Celine Christine
- SEC Form 4 filed by Director Mirviss Jeffrey B.
- New insider Mirviss Jeffrey B. claimed no ownership of stock in the company (SEC Form 3)
- New insider Martin Celine Christine claimed no ownership of stock in the company (SEC Form 3)
- CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
- CONMED downgraded by BofA Securities with a new price target
- CONMED Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
Latest LIVN
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)